Glucose Clamping made in Germany at ADA 2021
Meet the people behind Profil
About the ADA Scientific Sessions
Like every year, Profil will be present at the ADA Scientific Sessions. We will have posters as well as some talks. Of course we look forward to this exciting event very much.
Here is a list of our scientific contributions at the ADA Scientific Sessions
Monday, 8:00 - 10:00am, session at 8:10am
"Management of Type 1 Diabetes in Adults—2021 Draft ADA/EASD Consensus Report-section 'Diagnosis of type 1 diabetes' (Hans DeVries)"
- 197-OR - ADO09, A Co-formulation Of Insulin A21G And Pramlintide (pram) Improves Blood Glucose Control And Reduces Body Weight In Subjects With T1D
- 190-OR - Faster Recovery from Hyperglycemia with Ultra Rapid Lispro (URLi) vs Humalog® in Patients with Type 1 Diabetes (T1D) on Continuous Subcutaneous Insulin Infusion (CSII)
- 738-P - Proposed Biosimilar Gan & Lee Insulin Aspart (GL-ASP) Shows Pharmacokinetic (PK) And Pharmacodynamic (PD) Bioequivalence (BE) To US- And EU-licensed Insulin Aspart (ASP)
- 736-P - Proposed Biosimilar Gan & Lee Insulin Lispro (GL-LIS) Shows Pharmacokinetic (PK) And Pharmacodynamic (PD) Bioequivalence (BE) Versus US- And EU-licensed Insulin Lispro (LIS)
- 740-P - Proposed Biosimilar Gan & Lee Insulin Glargine (GL-GLA) Shows Pharmacokinetic (PK) And Pharmacodynamic (PD) Bioequivalence (BE) To US- And EU-licensed Insulin Glargine (IG)
- 342-P - Effects of Sitagliptin on Hypoglycemic Episodes and Counterregulation in Type 2 Diabetic Patients Tightly Titrated with Insulin glargine
- 728-P - Mylan Insulin Aspart (MYL-1601D) is bioequivalent to NovoLog (US licensed Insulin Aspart) and NovoRapid (EU-approved Insulin Aspart)
Other things you should know about the ADA Scientific Sessions
You can arrange a virtual meeting with a Profil representative at the occasion of the ADA Scientific Sessions to discuss your research or product developments. Just send an email to email@example.com or fill out the form on the right.